Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group

scientific article published on 10 February 2020

Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/S41375-020-0727-Y
P698PubMed publication ID32042081

P50authorJasmin BahloQ108428543
Ursula Vehling-KaiserQ47158556
Barbara EichhorstQ47158788
Stephan StilgenbauerQ47158807
P2093author name stringMichael Hallek
Andreas Bühler
Dirk Winkler
Georg Hopfinger
Hartmut Döhner
Raymonde Busch
Ulrich Jäger
Lothar Müller
Harald Fuss
Michael Starck
Martin Bentz
Carmen D Herling
Kirsten Fischer
Frank Hartmann
Bertold Emmerich
Werner Freier
Wolfgang Abenhardt
Georg Jacobs
Sandra Robrecht
Clemens Wendtner
Hans Jürgen Hurtz
Ilona Blau
Manuela A Hoechstetter
Maria Goebeler
Michael J Eckart
P2860cites workDefinition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemiaQ47812640
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.Q55036524
Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter O-CLL1-GISL studyQ60596975
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impactQ64091853
Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significanceQ70026398
Defining the prognosis of early stage chronic lymphocytic leukaemia patientsQ82972787
The CLL-IPI applied in a population-based cohortQ88291952
Growth dynamics in naturally progressing chronic lymphocytic leukaemiaQ92382869
Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patientsQ93055959
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-upQ27851444
Recurrent mutations refine prognosis in chronic lymphocytic leukemia.Q27853022
Genomic aberrations and survival in chronic lymphocytic leukemiaQ28141442
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemiaQ28394721
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemiaQ29614659
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient dataQ31096565
Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemiaQ33455289
The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experienceQ33707448
Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemiaQ33852805
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysisQ34282319
Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytomaQ34403901
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemiaQ34418874
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemiaQ36843749
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatmentQ36961269
Validation of a new prognostic index for patients with chronic lymphocytic leukemiaQ37068125
Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed?Q38680890
Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study groupQ40084503
Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.Q40365566
Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients.Q42336286
The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients.Q42711562
Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parametersQ42925708
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemiaQ44078664
Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL.Q44279397
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemiaQ44904842
P433issue4
P921main subjectmulticenter clinical trialQ6934595
P304page(s)1038-1051
P577publication date2020-02-10
P1433published inLeukemiaQ6534498
P1476titlePrognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group
P478volume34

Reverse relations

cites work (P2860)
Q94562886Chronic lymphocytic leukemia in 2020: a surfeit of riches?
Q99557890Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia
Q101051264Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients

Search more.